Protego Health Announces Strategic Partnership with Utah’s Ogden Clinic
Partnership Brings AI-Powered Denial Prevention and Appeals Automation to 250-Provider GroupNEW YORK, Dec. 17, 2025 /PRNewswire/ -- Protego Health, a leading...
Neurology
Xtalks Releases 2025 Webinar Year-in-Review Showcasing Key Life Science Trends
TORONTO, Dec. 17, 2025 /PRNewswire/ -- Xtalks — The Life Science Community™, a leading B2B digital media platform serving the...
KIFFIK Biomedical Closes Oversubscribed Series A to Advance Real-Time Molecular Diagnostics Platform
MIAMI, FL / ACCESS Newswire / December 17, 2025 / KIFFIK Biomedical announced today the successful close of its Series...
CNS Pharmaceuticals Announces CEO Transition
Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17,...
Aidoc Deepens Clinical AI Leadership Through Strategic Partnerships in Neurosciences
Collaborations with Cercare Medical and Circle CVI bring advanced AI for MR Perfusion and automated ASPECTS scoring to Aidoc's aiOS™...
Aidoc Deepens Clinical AI Leadership Through Strategic Partnerships in Neurosciences
Collaborations with Cercare Medical and Circle CVI bring advanced AI for MR Perfusion and automated ASPECTS scoring to Aidoc's aiOS™...
PhaseV Closes 2025 with Record Growth, Supporting Biopharma’s Shift from AI Pilots to Full-Scale Execution
Company Enters 2026 Positioned for Wide-Scale Deployment, Fueled by $50M Series A, 40+ Global Sponsors, and Measurable ROIBOSTON, Dec. 16,...
PhaseV Closes 2025 with Record Growth, Supporting Biopharma’s Shift from AI Pilots to Full-Scale Execution
Company Enters 2026 Positioned for Wide-Scale Deployment, Fueled by $50M Series A, 40+ Global Sponsors, and Measurable ROIBOSTON, Dec. 16,...
Cadwell and Medical Informatics Corp. Announce Partnership to Bring Neurodiagnostic Data into Clinical Intelligence Ecosystem
KENNEWICK, Wash. and HOUSTON, Dec. 11, 2025 /PRNewswire/ -- Cadwell, a global leader in neurodiagnostic and monitoring solutions, and Medical...
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China
Publication in key market advances NewcelX's global IP strategy across Asia and supports the Company's expanding position in neurology and...
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease Results show, for...
Bausch Health Announces Early Exchange Offer Results for Exchange Offers
LAVAL, QC / ACCESS Newswire / December 8, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") announced today the...
Imre taps Ogilvy’s Nadine Lafond as CEO to lead bold, new phase of agency evolution
NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Imre today announced the appointment of Nadine Lafond as its new Chief Executive...
Evotec Closes Sale of Just – Evotec Biologics’ Toulouse Site to Sandoz
All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in NovemberAgreement includes...
Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinson’s Disease
Phase 2 results selected as one of only 10 featured presentations in the Poster Tour at the 2025 Parkinson Study...
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)...
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1...
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire...
BTT Medical Institute Announces Unprecedented Case of Total Reversal of ALS through Re-engineering of the Nobel Prize-Winning Fever Therapy into a Brain-Guided, Artificial Intelligence-Controlled ThermoFebrile Treatment
First video-documented ALS reversal marks a new era for brain health achieved through noninvasive computerized brain-temperature modulation, confirmed by electrophysiological,...
Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome
Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndromeMilestone payment to Evotec expected upon...